Black and white women who received neoadjuvant therapy were equally likely to have pathologic complete response
Analysis of data from the I-SPY 2 clinical trial showed that race did not significantly affect several key measures of breast cancer treatment outcomes, including pathologic complete response and event-free survival, according ...